Aitia, which rebranded from GNS Healthcare in May 2023, is a pioneering company in the application of Causal AI and simulation technology to transform drug discovery and development. Aitia develops 'Gemini' Digital Twins—mechanistic, in-silico patient models that simulate disease progression and drug responses at an individual level. This cutting-edge approach enables biopharmaceutical partners to discover novel drug targets, predict patient responses, optimize clinical trial designs, and accelerate the delivery of personalized medicines. Aitia's primary focus areas include oncology, immunology, and neurodegenerative diseases, aiming to de-risk R&D and bring effective therapies to patients more rapidly.
Serves as the company's primary center for research, development of its Causal AI platform and Gemini Digital Twins, client engagement, and overall corporate strategy and operations.
State-of-the-art office space situated in Kendall Square, fostering collaboration and innovation. The location provides unparalleled access to leading academic institutions, research hospitals, and a vibrant biotech ecosystem.
Aitia cultivates a highly scientific, innovative, and collaborative work culture. The team is driven by a shared mission to transform patient outcomes through data-driven discoveries. There is a strong emphasis on interdisciplinary teamwork, intellectual curiosity, and translating complex science into impactful healthcare solutions.
The Cambridge headquarters is central to Aitia's identity and mission, housing the core talent and technology that drive its advancements in AI-powered drug discovery. Its location in a premier biotech hub facilitates key partnerships and talent acquisition.
While its physical operations are centered in Cambridge, MA, Aitia's influence and collaborations are global. The company partners with major biopharmaceutical companies, academic research centers, and healthcare systems across North America, Europe, and Asia. Its Causal AI platform and Gemini Digital Twins are applied to diverse therapeutic areas and patient populations worldwide, supporting global efforts in drug discovery and precision medicine.
One Main Street, 13th Floor
Cambridge
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aitia' leadership includes:
Aitia has been backed by several prominent investors over the years, including:
Aitia has focused on strengthening its executive team to support its growth and leadership in AI-driven drug development, highlighted by a key strategic hire in medical leadership.
Discover the tools Aitia uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Aitia (formerly GNS Healthcare) likely uses common corporate email formats for its employees. The most probable patterns involve combinations of first name, last name, or initials followed by '@aitia.com'.
[first_initial][last]@aitia.com (e.g., jdoe@aitia.com) and [first].[last]@aitia.com (e.g., jane.doe@aitia.com)
Format
chill@aitia.com
Example
80%
Success rate
Business Wire • October 17, 2023
Aitia appointed Dr. Jedd D. Wolchok, a leading figure in immuno-oncology, as its Chief Medical Officer. He will spearhead the company's clinical strategy and leverage his expertise to advance Aitia's causal AI-driven drug development programs....more
Business Wire • May 23, 2023
GNS Healthcare announced its corporate rebrand to Aitia. The new name and brand identity reflect the company's evolution and singular focus on Causal AI and Gemini Digital Twins to discover the next generation of breakthrough drugs and accelerate their development....more
Business Wire • March 14, 2023
GNS Healthcare (now Aitia) and Daiichi Sankyo initiated a research collaboration to utilize GNS's REFS™ Causal AI and simulation platform. The partnership aims to discover novel therapeutic targets and create new patient stratification biomarkers, initially focusing on key oncogenic pathways....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aitia, are just a search away.